| Enzo Biochem to Present at 9th Annual Needham Healthcare Conference (Business Wire) NEW YORK----Enzo Biochem, Inc. , a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today that Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will be presenting at the 9th annual Needham Healthcare Conference on Thursday, June 10th, 2010 at 3:20 PM at The New York Palace Hotel in New York, N.Y. us.rd.yahoo.com |
NeoStem Overreacts to Fear of Dilution M.E. Garza submits: If you don't follow the company closely, you may not realize the significance of Tuesday's news announcement from NeoStem (AMEX:NBS), but the details are definitely worth noting. NBS announced Tuesday that its Suzhou Erye pharmaceutical subsidiary in China passed government inspection by that country's State Food and Drug Administration and they will now be allowed to manufacture penicillin and cephalosporin powder for injection at the company's new manufacturing facility.Complete Story » seekingalpha.com |
CVS/pharmacy offers flu shots - Video CVS/pharmacy and MinuteClinic Offer “Flu Shots Your Way” At All Locations Nationwide feedproxy.google.com |
2 Year-End FDA Run-Up Stock Plays Mike Havrilla submits:Below are two small-cap stocks with expected FDA decisions by year-end and stock prices below $5 per share that I currently own as potential run-up plays with PDUFA action goal dates in late December for pending New Drug Applications (NDAs).On 8/30/10, Alimera Sciences (ALIM) was granted a priority (six-month) review for the ILUVIEN NDA that was filed 6/29/10 with expected FDA decision by 12/29/10, seeking approval for diabetic macular edema (DME). pSivida (PSDV) is due to receive $25M upon FDA approval + 20% profit sharing. In addition a MAA was filed for EU approval 7/8/10, and ALIM expects to complete the 3-year FAME study by year-end 2010 (this data not required for NDA), also expects to file a New Drug Submission (NDS) for Health Canada approval this month.Complete Story » seekingalpha.com |
Cardiovascular risk reduction for diabetics? - Video ACCORD Lipid Study brings new hope to people with type 2 diabetes and atherogenic dyslipidemia says international academic foundation feedproxy.google.com |